Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long Term Safety of Suvorexant in Primary Insomnia
NCT01021813Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2009
- Primary completion
- May 2011
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Insomnia comparing Suvorexant with Placebo (2 arms). Primary endpoints: Percentage of Participants Who Experienced Cataplexy Adverse Events at 12 months, Percentage of Participants Who Experienced Sleep Paralysis Adverse Events at 12 months and 5 more. Started Dec 2009; status: completed.
02
Drugs
suvorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT01021813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01021813.